Which has stronger valuation & earnings, CYPH or KARD?

Kardigan is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M $0.56 5.07 Kardigan N/A N/A -$191.94M -$2.88 N/A

Is CYPH or KARD more profitable?

Kardigan's return on equity of 0.00% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -20.76% -19.48% Kardigan N/A N/A N/A

Which has preferable valuation & earnings, DMRA or CYPH?

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A Cypherpunk Technologies N/A N/A $4.82M $0.56 5.07

Is DMRA or CYPH more profitable?

Cypherpunk Technologies' return on equity of -20.76% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Cypherpunk Technologies N/A -20.76% -19.48%

Which has better valuation & earnings, CYPH or NBTX?

Cypherpunk Technologies has higher earnings, but lower revenue than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M $0.56 5.07 Nanobiotix $36.87M 29.50 -$27.11M N/A N/A

Is CYPH or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -20.76% -19.48% Nanobiotix N/A N/A N/A

Which has stronger valuation and earnings, ORIC or CYPH?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A Cypherpunk Technologies N/A N/A $4.82M $0.56 5.07

Is ORIC or CYPH more profitable?

Cypherpunk Technologies' return on equity of -20.76% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Cypherpunk Technologies N/A -20.76% -19.48%

Which has preferable valuation & earnings, CYPH or REPL?

Replimune Group is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M $0.56 5.07 Replimune Group N/A N/A -$313.94M -$3.15 N/A

Is CYPH or REPL more profitable?

Cypherpunk Technologies' return on equity of -20.76% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -20.76% -19.48% Replimune Group N/A -159.32% -90.84%

Cypherpunk Technologies (CYPH) Competitors

$2.84 -0.06 (-2.07%)

As of 10/13/2026 04:00 PM Eastern

Compare

CYPH vs. KARD, DMRA, NBTX, ORIC, and REPL

Should you buy Cypherpunk Technologies stock or one of its competitors? Cypherpunk Technologies's main competitors and comparable companies include Kardigan (KARD), Damora Therapeutics, Inc. Common Stock (DMRA), Nanobiotix (NBTX), Oric Pharmaceuticals (ORIC), and Replimune Group (REPL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cypherpunk Technologies compare to Kardigan?

Cypherpunk Technologies (NASDAQ:CYPH) and Kardigan (NASDAQ:KARD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

30.5% of Cypherpunk Technologies shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kardigan's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-20.76%	-19.48%
Kardigan	N/A	N/A	N/A

In the previous week, Kardigan had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Kardigan and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.74 beat Kardigan's score of 0.41 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
Kardigan	Neutral

Cypherpunk Technologies presently has a consensus price target of $4.90, suggesting a potential upside of 72.54%. Kardigan has a consensus price target of $38.80, suggesting a potential upside of 199.15%. Given Kardigan's stronger consensus rating and higher possible upside, analysts plainly believe Kardigan is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kardigan	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Kardigan is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	5.07
Kardigan	N/A	N/A	-$191.94M	-$2.88	N/A

Summary

Kardigan beats Cypherpunk Technologies on 6 of the 11 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	5.07

Damora Therapeutics, Inc. Common Stock has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $46.50, indicating a potential upside of 150.54%. Cypherpunk Technologies has a consensus price target of $4.90, indicating a potential upside of 72.54%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, equities research analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cypherpunk Technologies' return on equity of -20.76% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

In the previous week, Damora Therapeutics, Inc. Common Stock had 3 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 4 mentions for Damora Therapeutics, Inc. Common Stock and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.74 beat Damora Therapeutics, Inc. Common Stock's score of 0.60 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Positive
Cypherpunk Technologies	Very Positive

Summary

Cypherpunk Technologies beats Damora Therapeutics, Inc. Common Stock on 7 of the 13 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Nanobiotix?

Cypherpunk Technologies (NASDAQ:CYPH) and Nanobiotix (NASDAQ:NBTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cypherpunk Technologies has higher earnings, but lower revenue than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	5.07
Nanobiotix	$36.87M	29.50	-$27.11M	N/A	N/A

Cypherpunk Technologies has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Nanobiotix's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-20.76%	-19.48%
Nanobiotix	N/A	N/A	N/A

In the previous week, Cypherpunk Technologies and Cypherpunk Technologies both had 1 articles in the media. Cypherpunk Technologies' average media sentiment score of 1.74 beat Nanobiotix's score of 0.89 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
Nanobiotix	Positive

Cypherpunk Technologies currently has a consensus target price of $4.90, indicating a potential upside of 72.54%. Nanobiotix has a consensus target price of $46.67, indicating a potential upside of 117.16%. Given Nanobiotix's stronger consensus rating and higher possible upside, analysts plainly believe Nanobiotix is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Nanobiotix beats Cypherpunk Technologies on 7 of the 11 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Oric Pharmaceuticals currently has a consensus price target of $20.67, indicating a potential upside of 82.73%. Cypherpunk Technologies has a consensus price target of $4.90, indicating a potential upside of 72.54%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Oric Pharmaceuticals is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Oric Pharmaceuticals and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.74 beat Oric Pharmaceuticals' score of 0.48 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Oric Pharmaceuticals	Neutral
Cypherpunk Technologies	Very Positive

Cypherpunk Technologies' return on equity of -20.76% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

Oric Pharmaceuticals has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	5.07

Summary

Oric Pharmaceuticals beats Cypherpunk Technologies on 7 of the 12 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Replimune Group?

Cypherpunk Technologies (NASDAQ:CYPH) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Replimune Group had 4 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 5 mentions for Replimune Group and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.74 beat Replimune Group's score of 0.70 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
Replimune Group	Positive

Cypherpunk Technologies' return on equity of -20.76% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-20.76%	-19.48%
Replimune Group	N/A	-159.32%	-90.84%

Cypherpunk Technologies has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Cypherpunk Technologies currently has a consensus target price of $4.90, suggesting a potential upside of 72.54%. Replimune Group has a consensus target price of $12.00, suggesting a potential downside of 0.91%. Given Cypherpunk Technologies' higher possible upside, equities analysts plainly believe Cypherpunk Technologies is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by insiders. Comparatively, 5.4% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Replimune Group is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	5.07
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

Summary

Replimune Group beats Cypherpunk Technologies on 7 of the 13 factors compared between the two stocks.

Get Cypherpunk Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYPH vs. The Competition

Export

Metric	Cypherpunk Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$312.52M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	10.43	199.17	19.37
Price / Sales	N/A	1,157.81	564.77	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.55	16.93	10.70	6.03
Net Income	$4.82M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-6.89%	-4.41%	-2.89%	-2.32%
1 Month Performance	10.08%	-12.46%	-7.36%	-5.29%
1 Year Performance	357.40%	7.64%	3.00%	-2.94%

Cypherpunk Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYPH Cypherpunk Technologies	2.3322 of 5 stars	$2.84 -2.1%	$4.90 +72.5%	+370.9%	$312.52M	N/A	N/A	40	Positive News Gap Down
KARD Kardigan	3.0672 of 5 stars	$14.20 +2.7%	$42.25 +197.5%	N/A	$1.29B	N/A	N/A	241	Analyst Forecast Short Interest Increase
DMRA Damora Therapeutics, Inc. Common Stock	3.2007 of 5 stars	$20.56 +1.6%	$46.50 +126.2%	+45.6%	$1.25B	N/A	N/A	40	Analyst Upgrade
NBTX Nanobiotix	3.3355 of 5 stars	$22.90 -7.0%	$46.67 +103.8%	-29.1%	$1.25B	$36.87M	N/A	97	Gap Down
ORIC Oric Pharmaceuticals	2.8913 of 5 stars	$12.03 +0.2%	$20.67 +71.8%	-18.7%	$1.24B	N/A	N/A	111

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYPH) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. KARD, DMRA, NBTX, ORIC, and REPL

How does Cypherpunk Technologies compare to Kardigan?

Summary

How does Cypherpunk Technologies compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Cypherpunk Technologies compare to Nanobiotix?

Summary

How does Cypherpunk Technologies compare to Oric Pharmaceuticals?

Summary

How does Cypherpunk Technologies compare to Replimune Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. KARD, DMRA, NBTX, ORIC, and REPL

How does Cypherpunk Technologies compare to Kardigan?

Do institutionals & insiders hold more shares of CYPH or KARD?

Is CYPH or KARD more profitable?

Does the media prefer CYPH or KARD?

Do analysts rate CYPH or KARD?

Which has stronger valuation & earnings, CYPH or KARD?

Summary

How does Cypherpunk Technologies compare to Damora Therapeutics, Inc. Common Stock?

Which has preferable valuation & earnings, DMRA or CYPH?

Which has more volatility & risk, DMRA or CYPH?

Do analysts prefer DMRA or CYPH?

Do insiders and institutionals hold more shares of DMRA or CYPH?

Is DMRA or CYPH more profitable?

Does the media favor DMRA or CYPH?

Summary

How does Cypherpunk Technologies compare to Nanobiotix?

Do insiders & institutionals believe in CYPH or NBTX?

Which has better valuation & earnings, CYPH or NBTX?

Which has more risk & volatility, CYPH or NBTX?

Is CYPH or NBTX more profitable?

Does the media favor CYPH or NBTX?

Do analysts recommend CYPH or NBTX?

Summary

How does Cypherpunk Technologies compare to Oric Pharmaceuticals?

Do institutionals and insiders believe in ORIC or CYPH?

Do analysts recommend ORIC or CYPH?

Does the media prefer ORIC or CYPH?

Is ORIC or CYPH more profitable?

Which has more volatility & risk, ORIC or CYPH?

Which has stronger valuation and earnings, ORIC or CYPH?

Summary

How does Cypherpunk Technologies compare to Replimune Group?

Does the media refer more to CYPH or REPL?

Is CYPH or REPL more profitable?

Which has more risk and volatility, CYPH or REPL?

Do analysts recommend CYPH or REPL?

Do insiders and institutionals have more ownership in CYPH or REPL?

Which has preferable valuation & earnings, CYPH or REPL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools